Table 4.

Serostatus to HPV-16 and 18 by competitive Luminex immunoassay (cLIA) and pseudovirion-based immunoassay (PBNA) positivity at baseline among all women and after vaccination

	N	cLIA*−/PBNA#−	cLIA+/PBNA+	cLIA+/PBNA−	cLIA-/PBNA+
Women in intent-to-treat group at baseline (% seropositive)
HPV-16 DNA-positive	5	1 (20%)	3 (60%)	0	1 (20%)
HPV-16 DNA-negative	111	74 (67%)	21 (19%)	5 (5%)	11 (10%)
HPV-18 DNA-positive	2	1 (50%)	1 (50%)	0	0
HPV-18 DNA-negative	114	85 (75%)	12 (11%)	7 (6%)	10 (9%)
Women in per-protocol group who were DNA negative at baseline (% seropositive)
HPV-16
Baseline
DNA-negative	102	68 (67%)	19 (19%)	5 (5%)	10 (10%)
Week 28
DNA-negative	93	0	92 (99%)	0	1 (1%)
DNA-positive	2	0	2 (100%)	0	0
Week 52
DNA-negative	97	1 (1%)	95 (98%)	0	1 (1%)
DNA-positive	0	0	0	0	0
HPV-18
Baseline
DNA-negative	104	77 (74%)	11 (11%)	7 (7%)	9 (9%)
Week 28
DNA-negative	96	5 (5%)	88 (92%)	1 (1%)	2 (2%)
DNA-positive	1	0	1 (100%)	0	0
Week 52
DNA-negative	97	15 (16%)	69 (71%)	4 (4%)	9 (9%)
DNA-positive	2	0	0	0	2 (100%)

^*cLIA, competitive Luminex immunoassay (cLIA)

^#PBNA, pseudovirion-based immunoassay (PBNA)